New BiTE Agent for Small Cell Lung Cancer Approved by the FDA.

Published Date: 20 May 2024

In previously treated extensive-stage SCLC, first-in-class tarlatamab achieved a 40 percent ORR.

Read Full News

Latest News



Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Antitumor mRNA-based vaccines show potential against gastric cancer metastasis

2.

Obesity-associated cancers may be on the rise in Puerto Rico

3.

Predicting adult mortality from oral cancer using a machine learning approach.

4.

Major Shifts in Urothelial Cancer Care: Immunotherapy Redefines Standards

5.

In R/R Follicular Lymphoma, Tisa-Cel Produces Long-Lasting Responses.


© Copyright 2025 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot